Backed by 66 billion euros in returns, European life science investment sounds the "loss warning"
- The European Federation of Pharmaceutical Industries and Associations issued a report on Tuesday warning that the current geopolitical and policy environment is putting Europe at risk of losing out in the global competition for life sciences investment.
- The association stressed that strengthening innovation conditions, ensuring new medicines are accessible in a timely and equitable manner, and maintaining Europe’s global competitiveness in the life sciences sector must be promoted as interconnected priorities, rather than being addressed separately.
- According to research commissioned by the association, between 2014 and 2024, Europe invested €11.67 billion in new drug research and development, while cumulative returns from increased labor productivity, contributions from both paid and unpaid work, and hospital cost savings have reached as much as €66 billion—yielding an input-output ratio of nearly 1:5.7.
- Against the backdrop of continued global trade disruption from Trump’s tariff remarks, the STOXX 600 Health Care Index rose 1.2% on Tuesday, reflecting partial market pricing for the sector’s resilience and policy concerns. Going forward, the focus will be on whether the European Union can translate the strategic priorities outlined in the report into concrete legislation and financial support, in order to curb the trend of investment outflows.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Elon Musk changes his stance! Tesla (TSLA.US) delays Cybertruck production halt to late summer 2027, just two days after suggesting “refund deposits”
Elon Musk stated that Cybertruck production will be extended until late summer 2027 to clear the order backlog, and Tesla's stock price rose by about 4%.
Japanese dovish policymaker urges "slow down": Price increases are not driven by demand, rate hikes may drag down the economy and inflation
Toichiro Asada, a member of the Bank of Japan's Policy Board, stated that the central bank needs to remain cautious and closely monitor the impact of rate hikes on the economy, as rising interest rates pose the risk of suppressing the inflation trend.
Don't Be Misled by "Instant Purchase, Instant Access": Pro Series Zero Wait Has Been the Norm for Years, UBS Maintains Apple (AAPL.US) Target Price at $340
The waiting time for iPhone 18 Pro is approaching zero, and Duo deliveries are scheduled until the end of January. UBS maintains its forecast for iPhone revenue in the December quarter at $95.1 billions, representing a year-on-year increase of 11.5%.
Crypto prices
More
